The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype
Top Cited Papers
- 31 October 2007
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 83 (2), 234-242
- https://doi.org/10.1038/sj.clpt.6100406
Abstract
Inferring CYP2D6 phenotype from genotype is increasingly challenging, considering the growing number of alleles and their range of activity. This complexity poses a challenge in translational research where genotyping is being considered as a tool to personalize drug therapy. To simplify genotype interpretation and improve phenotype prediction, we evaluated the utility of an "activity score" (AS) system. Over 25 CYP2D6 allelic variants were genotyped in 672 subjects of primarily Caucasian and African-American heritage. The ability of genotype and AS to accurately predict phenotype using the CYP2D6 probe substrate dextromethorphan was evaluated using linear regression and clustering methods. Phenotype prediction, given as a probability for each AS group, was most accurate if ethnicity was considered; among subjects with genotypes containing a CYP2D6*2 allele, CYP2D6 activity was significantly slower in African Americans compared to Caucasians. The AS tool warrants further prospective evaluation for CYP2D6 substrates and in additional ethnic populations.Keywords
This publication has 32 references indexed in Scilit:
- Ontogeny of Dextromethorphan O- and N-demethylation in the First Year of LifeClinical Pharmacology & Therapeutics, 2007
- CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testingThe Pharmacogenomics Journal, 2006
- Identification of CYP2D6 impaired functional alleles in Mexican AmericansEuropean Journal of Clinical Pharmacology, 2005
- Substrate specific metabolism by polymorphic cytochrome P450 2D6 allelesToxicology in Vitro, 2005
- Allele-Specific Change of Concentration and Functional Gene Dose for the Prediction of Steady-State Serum Concentrations of Amitriptyline and Nortriptyline in CYP2C19 and CYP2D6 Extensive and Intermediate MetabolizersClinical Chemistry, 2004
- Unique CYP2D6 activity distribution and genotype‐phenotype discordance in black AmericansClinical Pharmacology & Therapeutics, 2002
- The African‐specific CYP2D6*17 allele encodes an enzyme with changed substrate specificityClinical Pharmacology & Therapeutics, 2001
- Analysis of the gene in relation to dextromethorphan -demethylation capacity in a Japanese populationClinical Pharmacology & Therapeutics, 1999
- Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German populationPharmacogenetics, 1998
- A Combination of Mutations in theCYP2D6*17(CYP2D6Z) Allele Causes Alterations in Enzyme FunctionPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,1997